A number of other equities research analysts have also recently commented on the company. HC Wainwright reaffirmed a neutral rating on shares of Rewalk Robotics in a research note on Friday, March 15th. Cantor Fitzgerald set a $8.00 price objective on BioDelivery Sciences International and gave the stock a buy rating in a research note on Friday, May 10th. Zacks Investment Research cut HENGAN INTL GRP/ADR from a strong-buy rating to a hold rating in a research note on Tuesday, May 21st. Finally, SunTrust Banks assumed coverage on Zoetis in a research note on Tuesday, March 19th. They set a hold rating and a $100.00 price objective for the company. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $6.20.
Shares of BioDelivery Sciences International stock opened at $4.07 on Friday. The company has a quick ratio of 2.57, a current ratio of 2.88 and a debt-to-equity ratio of 1.90. BioDelivery Sciences International has a 12 month low of $2.35 and a 12 month high of $5.37. The business’s fifty day moving average is $4.41.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. BioDelivery Sciences International had a negative return on equity of 43.40% and a negative net margin of 42.09%. The business had revenue of $19.77 million during the quarter, compared to analysts’ expectations of $19.60 million. As a group, equities research analysts anticipate that BioDelivery Sciences International will post -0.14 earnings per share for the current fiscal year.
In other BioDelivery Sciences International news, CEO Herm Cukier sold 30,285 shares of BioDelivery Sciences International stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $5.07, for a total transaction of $153,544.95. Following the transaction, the chief executive officer now directly owns 66,666 shares in the company, valued at $337,996.62. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Healthcare Master Fun Broadfin sold 1,800,000 shares of BioDelivery Sciences International stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $5.00, for a total value of $9,000,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,429,743 shares of company stock worth $11,707,558. Corporate insiders own 8.94% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. QCM Cayman Ltd. bought a new position in BioDelivery Sciences International during the first quarter worth about $35,000. Advisor Group Inc. lifted its holdings in BioDelivery Sciences International by 56.3% during the fourth quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock worth $40,000 after acquiring an additional 3,943 shares in the last quarter. First Allied Advisory Services Inc. bought a new position in BioDelivery Sciences International during the first quarter worth about $58,000. Means Investment CO. Inc. bought a new position in BioDelivery Sciences International during the first quarter worth about $59,000. Finally, Close Asset Management Ltd lifted its holdings in BioDelivery Sciences International by 1,340.0% during the first quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock worth $95,000 after acquiring an additional 16,750 shares in the last quarter. Hedge funds and other institutional investors own 56.73% of the company’s stock.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Recommended Story: Return on Investment (ROI)
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.